Clinical significance and role of coinfections with respiratory pathogens among individuals with confirmed severe acute respiratory syndrome coronavirus-2 infection

Ivelina Trifonova1*, Iva Christova2, Iveta Madzharova3, Svetla Angelova2, Silvya Voleva3, Ralitsa Yordanova3, Tatiana Tcherveniakova3, Stefka Krumova1 and Neli Korsun1

1National Laboratory “Influenza and ARD”, Department of Virology, National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria, 2Clinical Virology Laboratory, University Hospital “Prof. Dr. Stoyan Kirkovich”, Stara Zagora, Bulgaria, 3Clinic for Neuro Infections, Airborne, Roof, and Transmissible Infections, Infectious Hospital “Prof. Ivan Kirov”, Department of Infectious Diseases, Parasitology and Tropical Medicine, Medical University of Sofia, Sofia, Bulgaria

Introduction: This study aimed to determine the prevalence, viral profile, and clinical features of coinfections with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and other respiratory viruses.

Methods: Nasopharyngeal samples and clinical data of 221 hospitalized patients and 21 outpatients were collected and analyzed. Real-time reverse transcription-polymerase chain reaction was used to detect SARS-CoV-2, influenza virus, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza virus (PIV), 1, 2, 3, rhinovirus (RV), adenovirus (AdV), bocaviruses (BoV), and seasonal coronaviruses (OC43, 229E, NL63, and HKU1). Viral load was determined by capillary electrophoresis.

Results: From November 2020 to mid-March 2022, 242 SARS-CoV-2 positive patients were tested for seasonal respiratory viruses, and 24 (9.9%) cases of coinfections were detected. The distribution of viruses involved in cases of coinfections were as follows: HMPV (n = 6; 25%), RSV (n = 4; 16.7%), AdV (n = 4; 16.7%), BoV (n = 4; 16.7%), PIV3 (n = 2; 8.3%), influenza A (H3N2; n = 2; 8.3%), RV (n = 1; 4.62%), and RV+BoV (n = 1; 4.62%). The proportion of detected coinfections with SARS-CoV-2 was highest in children aged 0–5 years (59%), followed by those >65 years (33%). In specimens with detected coinfection, the viral load of influenza was higher than that of SARS-CoV-2, and the mean viral load of SARS-CoV-2 was higher than that of the other respiratory viruses. C-reactive protein (CRP) and lymphocytes count in co-infected patients >65 years of age were on average higher than in children <16 years of age (mean CRP of 161.8 ± 133.1 mg/L; 19.7 ± 3.09% vs. mean 6.9 ± 8.9 mg/L, 0.9 ± 3.1%; p < 0.01). Patients >65 years of age co-infected with SARS-CoV-2 and other respiratory viruses had longer hospital stays than those <16 years of age (mean 9 ± 3.96 days vs. 5.44 ± 1.89 days; p = 0.025). The combination of AdV and SARS-CoV-2 is fatal for patients aged >65 years.
Introduction

Acute respiratory infections (ARI) cause significant morbidity and are associated with a large number of medical consultations, hospitalizations, and high medical and social costs. Over 200 species of viruses from different families with similar transmission mechanisms, tissue tropism, and clinical manifestations have been identified as etiological agents of acute upper and lower respiratory tract infections. Some respiratory viruses originating from the animal kingdom may acquire the ability to cause diseases in humans and spread rapidly in human society due to the lack of immunity in the human population, causing pandemics (1). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which emerged at the end of December 2019 in China, has become widespread globally, causing the largest pandemic in the last 100 years, with an enormous number of human casualties and serious consequences in many areas of human society (2).

Bulgaria has been hit hard by the coronavirus disease (COVID-19) pandemic, which caused more than 1.1 million infections and 36,950 related deaths as of April 2022. Given that Bulgaria’s population is 6.5 million, we can conclude that the pandemic has left its mark on the country’s demographics and is a challenge to the health system.

Strict non-pharmaceutical preventive interventions (social distancing, wearing face masks, reduced travel, closing schools and businesses, and hand hygiene) implemented to mitigate the diffusion of SARS-CoV-2 have had a significant impact on the prevalence and some aspects of the epidemiology of other respiratory viruses, such as the virus, age, and monthly distribution (3). No influenza virus was isolated from the country during the 2020–2021 season. In the following 2021–2022 season, the circulation of influenza viruses was significantly lower than in the pre-pandemic seasons, with a later peak incidence, which coincided with a period of loosening of the public health measures in March 2022.

The emergence of the new coronavirus against the background of an unusual decrease in the prevalence of respiratory viruses poses a new challenge to the laboratory team, as to whether co-infections between the new coronavirus and other respiratory viruses are possible, how often they occur, and how they affect the severity of the disease. In the first year of the pandemic, research in many laboratories in the country focused only on detecting the pandemic coronavirus, which precluded the diagnosis of other respiratory viral pathogens causing infections with similar clinical manifestation. Information on the prevalence of seasonal respiratory viruses in Bulgaria is very limited, despite published data on possible coinfections between SARS-CoV-2 and other respiratory viruses (4). SARS-CoV-2 causes a wide range of clinical manifestations ranging from asymptomatic or mild symptoms to severe or even critical illness and death (5). According to a number of researchers, coinfection between SARS-CoV-2 and other respiratory viruses can induce a more severe inflammatory process, which can aggravate the state of illness and cause unfavorable outcomes (6). Coinfections can be associated with an increased rate of complications, longer treatment duration, a higher rate of intensive care unit (ICU) admission, and mortality compared to a single infection (7, 8). However, other authors believe that coinfections with additional respiratory viruses do not worsen clinical severity and outcome. This is probably due to viral interference when one virus inhibits the replication of another virus through resource competition, by induction of interferon, or other immunological mechanisms (9). Early detection of viral coinfections may be helpful for patient management and prognosis and can prevent unnecessary use of antibiotics. The present study aimed to explore the coinfections with SARS-CoV-2 and other respiratory viruses to identify the respiratory viruses involved, to determine the possible link between the age of patients and the frequency of co-infections as well as the differences in viral loads of detected viruses in cases of coinfections and clinical manifestation in co-infected and monoinfected patients. The possible link between the occurrence of coinfections and the deterioration of the clinical picture in patients from different age groups is another aim of the study. Despite numerous publications on the subject, the question of the clinical relationship between co-infections remains unclear (10–14).

Conclusion: In patients aged >65 years, coinfection with SARS CoV-2 and other respiratory viruses, together with concomitant diseases, causes worsening of the clinical picture and complications, and can be fatal. Screening of patients with SARS CoV-2 for other respiratory viruses is needed to select appropriate treatments and prevent a fatal outcome of the disease.

KEYWORDS
coinfection, SARS-CoV-2, respiratory virus, viral load, clinical significance, COVID-19
Materials and methods

Study population and specimen sampling

Nasopharyngeal swabs from patients with confirmed SARS-CoV-2 infection, together with clinical and epidemiological data, were prospectively collected from both inpatients and outpatients. Hospitalized patients were treated in two hospitals located in distinct geographic regions. The swabs were placed in 2 ml medium (polyester collection swabs), stored on ice for transport to the national testing laboratory, and the swabs were stored at 4°C for up to 72 h before being sent to the laboratory. The samples were processed immediately or stored at −80°C before testing.

Nucleic acid extraction and reverse transcription polymerase chain reaction (RT-PCR)

Viral DNA and RNA were extracted by an automatic extraction system using the ExiPrep Dx Viral DNA/RNA kit (Bioneer, Daejon, Republic of Korea) in accordance with the manufacturer’s instructions. SARS-CoV-2 was detected by real-time RT-PCR using the TaqPath COVID-19 CE-IVD PCR Kit (Thermo Fisher Scientific). This kit specifically identifies three regions in the SARS-CoV-2 genome: N-gene, S-gene, and ORF ab. It has a clinical sensitivity of 100% [95% confidence interval (CI): 97.9–100.0%] and clinical specificity of 100% (95% CI: 98.6–100.0%). The detection limit was 250 copies/ml. Amplification was performed using the QuantStudio™ 5 real-time PCR system, 96-well (ThermoFisher Scientific).

SARS CoV-2-positive specimens were tested for influenza type A and B viruses, as well as for eight other seasonal respiratory viruses: respiratory syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza virus (PIV) types 1/2/3, rhinovirus (RV), adenovirus (AdV), bocavirus (BoV), and four seasonal human coronaviruses: OC43, 229E, NL63, and HKU1. Influenza A viruses are differentiated into A (H1N1) pdm09 and A (H3N2). Screening for influenza and non-influenza respiratory viruses was performed using singleplex real-time RT-PCR assays with the SuperScript III Platinum™ One-Step qRT-PCR System (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and the necessary primers. The SuperScript III Platinum One-Step qRT-PCR System (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and suitable primers were used to amplify the RdRp region of the SARS-CoV-2 genome.

Quantitative methods

Quantitative capillary electrophoresis was used to determine the viral load of each viral pathogen involved in the coinfection with SARS-CoV-2. The method was implemented using a QIAxcel Advanced capillary system. Gel cartridges were used in combination with a preprogrammed method, allowing the separation and analysis of DNA. The preparatory stage of the method included the amplification of genomic targets of the individual respiratory viruses using a commercial kit (Seeplex® RV15 OneStep ACE Detection) containing the necessary primers. The SuperScript III Platinum One-Step qRT-PCR System (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and suitable primers were used to amplify the RdRp region of the SARS-CoV-2 genome.

TABLE 1 Thermocycling conditions of real time polymerase chain reaction for detection of severe acute respiratory syndrome coronavirus-2, eight common respiratory viruses, four seasonal human coronaviruses, and influenza viruses.

| Thermocycling conditions of Real Time | Reverse transcription | Initial denaturation | Amplification - 40 cycles |
|--------------------------------------|----------------------|----------------------|--------------------------|
| RT-PCR for detection of SARS-CoV-2   | 53°C 10 min          | 95°C 2 min           | 95°C 3 sec 60°C 30 sec   |

| Thermocycling conditions of Real Time | Reverse transcription | Initial denaturation | Amplification - 44 cycles |
|--------------------------------------|----------------------|----------------------|--------------------------|
| RT-PCR for detection of RSV, HMPV, PIV1,2,3, RV, AdV and BoV | 45°C 10 min     | 95°C 10 min            | 94°C 30 sec 57°C 1 min |

| Thermocycling conditions of Real Time | Reverse transcription | Initial denaturation | Amplification - 44 cycles |
|--------------------------------------|----------------------|----------------------|--------------------------|
| RT-PCR for detection of coronaviruses OC43, 229E, NL63 and HKU1 | 48°C 20 min     | 95°C 5 min                | 95°C 15 sec 55°C 1 min |

| Thermocycling conditions of Real Time | Reverse transcription | Initial denaturation | Amplification - 44 cycles |
|--------------------------------------|----------------------|----------------------|--------------------------|
| RT-PCR for detection of influenza viruses | 50°C 30 min     | 95°C 2 min                | 94°C 15 sec 56°C 30 sec |

The thermocycling conditions for real-time PCR assays are listed in Table 1.
A formula converting the concentration of viral amplicons into viral copies was used:

\[
\text{Number of copies of DNA template of ul} = \frac{(\text{DNA concentration (ng/µl)} \times \text{Avogadro’s number})}{(\text{template length (bp)} \times \text{conversion factor to ng} \times \text{average weight of base pair (Da)})}
\]

\[
\text{Number of copies} = \frac{(\text{DNA concentration (ng/µl)} \times (6.022 \times 10^{23}))}{(\text{pattern length (bp)} \times [1 \times 10^9] \times 660)}
\]

To determine the concentration of the amplicons (ng/µl) and the length of the amplified region of the viral genome [base pairs (bp)], we used capillary electrophoresis.

We had in mind that the mass of the DNA nucleotide was 330 Da, and the mass of the bp in the double-stranded DNA was 660 Da. In this formula, the weight of the DNA nucleotide was 330 g, and the weight of the bp formula in double-stranded DNA was 660 g. In this expression, the number of moles present in 1 g of material is inversely proportional to the weight. Avogadro’s number, \(6.022 \times 10^{23}\) molecules/mol, was used to calculate the number of molecules per gram. The number of copies of the template in the sample was obtained by multiplying by \(1 \times 10^9\) to convert to ng/µl and then multiplying by the amount of template (in ng/µl).

### Clinical data and definitions

The assessment of patients was based on the assessment of the condition of patients using a category scale (8, 18).

1- is not hospitalized with resumption of normal activity;
2- is not hospitalized, but cannot resume normal activities;
3- hospitalized, not requiring additional oxygen;
4- hospitalized, requiring additional oxygen;
5- hospitalized requiring high-flow nasal oxygen therapy, non-invasive mechanical ventilation, or both;
6- hospitalized, requiring ECMO, invasive mechanical ventilation, or both;
7- death.

We used data from the described epicrisis for each doctor, with a specialist in the field participating in the analysis. The patient’s medical record presented demographic data, comorbidities presenting symptoms and signs, blood biochemical indices, use of antivirals and antibiotics, corticosteroids and bronchodilator drugs, intensive care, length of hospital stay, need for artificial ventilation, and adverse events classified according to the criteria of the National Cancer Institute for adverse events, version 4.0.

Pneumonia was determined by X-ray examination and the presence of pulmonary infiltrates. Acute respiratory distress is defined again by the definition of Berlin (19).

### Statistical analysis

Chi-square or Fisher’s exact tests were used to assess categorical variables, which were presented as total counts and percentages. Continuous variables were compared using a paired comparison plot, Fisher LSD, t-test, and Mann–Whitney U-test. Differences with \(p\)-values < 0.05 were considered as statistically significant. The statistical software package Origin: Data Analysis and Graphing Software was used. The Cox regression method is also applied, according to the \(p\)-value it is determined accordingly whether the regression coefficient is significantly different from zero.

### Results

#### Characterization of the group of studied patients

This study covered the period from November 2020 to mid-March 2022 and included 242 SARS-CoV-2 positive patients, of which 221 (91.52%) were hospitalized and 21 (8.7%) were outpatients. Bases for sampling were two hospitals - Infectious Diseases Hospital “Prof. Ivan Kirov” in Sofia where 148 of study patients were treated and University Hospital “Prof. Dr. Stoyan Kirkovich”, Stara Zagora with 73 study patients. Fifteen (6.2%) patients were admitted to the ICU. The mortality rate of hospitalized patients was 9.5%. Outpatient specimens were collected from the hospital emergency center. Patient age varied from 10 days to 90 years (mean age 47 ± 32.11 years; median age 65 years). The distribution of patients by age was as follows: 35 (22.7%) were 0–5 years old, 27 (11.2%) were 6–16 years old, 36 (14.9%) were 17–64 old, and 124 (51.2%) were >65 years old. The number of male patients studied (121) was equal to that of female patients.

#### Identification of coinfections in SARS-CoV-2 positive patients

Among the 242 patients, who were diagnosed with COVID-19, coinfection with other respiratory viruses was detected in 24 (9.9%) patients: 23 (95.8%) were coinfecte
with a single respiratory virus, and one (4.2%) was coinfected with two viruses. The proportions of coinfections among SARS CoV-2 positive inpatients and outpatients were 21/221 (9.5%) and 3/21 (12.5%), respectively. Among the coinfected patients, one (4.2%) required ICU admission and another (4.2%) had a fatal outcome. HMPV was the most commonly identified co-detecting virus ($n = 6$, 25%), followed by RSV, AdV, and BoV, which were identified with equal frequency ($n = 4$, 16.7%). The combinations of SARS CoV-2 with other pathogens, PIV3 ($n = 2$, 8.3%), influenza A ($H3N2$; $n = 2$, 8.3%), and RV ($n = 1$, 4.62%), were found relatively less frequent. SARS-CoV, RV, and BoV were detected only in triple infections.

To evaluate the co-circulation of the four seasonal human coronaviruses during the COVID-19 pandemic, we examined 155 (64%) of the patients. In this target group, co-infections between SARS-CoV-2 and the OC43, NL63, 229E, and HKU-1 viruses were not found.

Seasonal and age distribution of detected coinfections in SARS-CoV-2 positive patients

During the COVID-19 pandemic, the highest number of coinfections with SARS-CoV-2 and other viral respiratory pathogens was identified in March 2021 (51/242, 33%), followed by those detected in November 2020, February 2021, July 2021, and January 2022, with detection rates of 8.3%. In December 2020, combinations of SARS-CoV-2 with AdV and SARS-CoV-2 with RSV were more frequently identified, and in September 2021 and December 2021, coinfections between SARS-CoV-2 and HMPV were more frequent. No influenza virus was detected in Bulgaria during the 2020/2021 season. In the 2021/2022 season, only influenza A ($H3N2$) virus circulated in the country. Two cases of coinfections between SARS-CoV-2 and influenza A ($H3N2$) were detected in January and March 2022 (Figure 1).

In this study, coinfections were detected in SARS-CoV-2-positive patients from all age groups (0–5, 6–16, 17–64, and 65+ years), and proportions of coinfections were 59, 4, 4, and 33%, respectively (Figure 2). The rate of coinfections was highest in the youngest patients (0–5 years), accounting for 25.4% of all cases in this age group, followed by adults ≥65 years (6.5%). Coinfections with SARS-CoV-2 and other respiratory viruses were less common in patients aged 5–16 years (3.9%) and 17–64 years (2.8%). The combination of SARS-CoV-2 and BoV was detected in the youngest children (16.7%), whereas in other age groups, no cases of this coinfection were detected. In the oldest patients, coinfections with HMPV were the most frequent (20.8%), while in children aged 0–5 years, they accounted for 4.7%. Two 13- and 3-year old patients were diagnosed with coinfections, including influenza A ($H3N2$) virus, with a detection rate of 4.7% for all coinfections, including SARS-CoV-2.

Viral load of respiratory viruses involved in coinfections with SARS-CoV-2 determined by quantitative capillary electrophoresis

In this study, we compared the viral loads of SARS-CoV-2 with those of other respiratory viruses (HMPV, RSV, RV, AdV, BoV, and PIV3) involved in coinfections. We found that the mean value of the SARS-CoV-2 viral load ($1.79E8 \pm 4.00$ virus copies/ml; Figure 3B) was higher than that of the six co-detecting respiratory viruses ($1.74E7 \pm 1.77$ virus copies/ml; $p$
FIGURE 2
Age distribution of coinfected patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and other respiratory viruses. Monoinfected patients are positive for SARS-CoV-2.

< 0.001; Figure 3C). In patients with influenza A (H3N2)/SARS-CoV-2 coinfection, the mean influenza viral load (8.77E9 ± 1.12E10 viral copies/ml) was higher than that of SARS-CoV-2 (1.17E8 ± 1.41E6 viral copies/ml; p < 0.001; Figure 3D). We compared the viral loads of the six detected respiratory viruses in patients infected with SARS-CoV-2 with those of influenza viruses and found significant differences (p < 0.001). Accordingly, influenza viruses had a higher viral load than those of the six respiratory viruses involved in coinfections with SARS-CoV-2 (1.75E7 ± 1.77E7 viral copies/ml vs. 1.17E8 ± 1.41E6 viral copies/ml; Figure 3A).

Clinical data of study patients

Demographic, clinical, treatment, and laboratory data of the study patients were extracted from medical records. In children and adolescents <16 years of age, no sharp deterioration in the clinical picture or progression to a severe form of COVID-19 was observed. In co-infected children with SARS-CoV-2 and other respiratory viruses, the saturation was normal, and frequently observed symptoms were fever in the range of 37.4°-40°C (89%) and diarrhea (11%). In patients >65 years of age, the clinical manifestations of COVID-19 were more pronounced, with the most common being dyspnea, cough, fatigue, loss of appetite, and some with diarrhea. In this age group, the proportion of patients with concomitant diseases was 70%, and the most common were hypertension (n = 24, 48.9%) and diabetes (n = 12, 24.5%). In hospitalized patients >65 years of age, the incidence of cases with dyspnea was 31.4%, dyspnea with cough was 58.3%, and a combination of two symptoms and intense treatment was 57.1%. A total of 15 (21.4%) patients >65 years of age needed intensive treatment, and four (26%) of them had concomitant hypertension. All hospitalized patients who received oxygen therapy (n = 38, 17.2%) were >65 years old. Over 84% of bedridden patients underwent antibiotic treatment. Out of 221 hospitalized patients with confirmed SARS-CoV-2 infection, fatal outcomes were reported in 24 (10.4%), and coinfection with AdV was detected in one (4.3%) of them. Co-infected patients >65 years of age with SARS-CoV-2 and other respiratory viruses required longer hospital stays (mean 9 ± 4.33 days) compared to those <16 years...
of age (5.44 ± 2.01 days; \( p = 0.05 \)). From the Cox regression results presented in Table 2, it is clear that there is an 11.9% increase in the risk of death with increasing time from disease onset to hospitalization (or an estimated risk of 0.83 times higher per day in patients with COVID-19 who did not seek timely hospitalization, \( p = 0.004 \)). The probability of fatal outcome was increased in co-infected patients in contrast to mono-infected patients by 25.3% (this result did not have statistical significance \( p = 0.37 \)). The 41.3% increased probability of death in intensive care patients was statistically significant (\( p = 0.002 \)).

Comparison of patients with mono- and coinfections

The Ct value provides a reliable means to quantify pathogen activity (a low Ct value corresponds to a high viral load in nasopharyngeal swabs). We compared the Ct values for SARS CoV-2 detection in patients with SARS CoV-2 mono- and coinfections. The mean Ct values did not differ significantly in cases of mono- and coinfections (24.46 ± 4.77 and 24.02 ± 5.84, respectively). However, the mean Ct value of SARS-CoV-2 was higher than that of the other respiratory pathogens in cases of coinfections (32.62 ± 5.69 vs 24.02 ± 5.84; \( p < 0.001 \); Figure 4).

The age of patients with mono- and coinfections, as well as some clinical and laboratory parameters, were also compared. The average age of patients with detected coinfections (26.9 ± 32.9 years) was younger in comparison to that of patients who only had SARS-CoV-2 infection (48.9 ± 31.5 years), and this difference was statistically significant (\( p < 0.001 \)).

In terms of clinical symptoms, fever, fatigue, and diarrhea (Table 3) were more frequently observed in patients with coinfections compared to those with only SARS-CoV-2 infections (\( p < 0.05 \)). In coinfected febrile patients, the mean
TABLE 2 Cox regression modeling of survival of patients with COVID-19 vs. time from disease onset to hospitalization, in co-infected patients and those requiring intensive care.

| Factor                                      | Coefficients | Lower 95% CI | Upper 95% CI | SE  | z  | p-Value | Exp (B) | Lower 95% CI | Upper 95% CI |
|---------------------------------------------|--------------|--------------|--------------|-----|----|---------|---------|--------------|--------------|
| Time from onset of illness to hospitalization | -0.18        | -0.3         | -0.06        | 0.06| 2.89| 0.004   | 0.83    | 0.74         | 0.94         |
| Coinfection                                | -0.93        | -2.97        | 1.12         | 1.04| 0.89| 0.374   | 0.4     | 0.05         | 3.06         |
| Intensive treatment                        | 1.42         | 0.54         | 2.3          | 0.45| 3.17| 0.002   | 4.13    | 1.72         | 9.95         |

TABLE 5 Clinical manifestations, treatment, and clinical adverse events in patients with severe acute respiratory syndrome coronavirus-2 mono- and co-infection with other respiratory viruses.

| SARS CoV-2 mono-infection (n = 218) | SARS CoV-2 co-infection with other respiratory virus (n = 24) | p-Value |
|-------------------------------------|---------------------------------------------------------------|---------|
| Symptoms                            |                                                               |         |
| Fever                               | 39 (17.9)                                                     | 14 (58.3) | <0.0001 |
| Fatigue                             | 24 (11)                                                       | 8 (33.3)  | 0.0022  |
| Shortness of breath                 | 22 (10.1)                                                    | 4 (16.7)  | 0.3235  |
| Wheezing                            | 25 (11.5)                                                    | 3 (12.5)  | 0.8807  |
| Cough                               | 29 (13.3)                                                    | 6 (25)    | 0.1220  |
| Diarrhea                            | 5 (2.3)                                                       | 3 (12.5)  | 0.0079  |
| Treatment                           |                                                               |         |
| Corticosteroids                     | 53 (24.3)                                                    | 5 (20.8)  | 0.7048  |
| Intravenous antibiotics             | 64 (29.4)                                                    | 9 (37.5)  | 0.4095  |
| Oxygen therapy                      | 38 (17.4)                                                    | 6 (25)    | 0.3615  |
| Ventilation support                 | 14 (6.4)                                                     | 1 (4.2)   | 0.6636  |
| Complications and clinical outcomes |                                                               |         |
| Acute heart failure                 | 10 (4.6)                                                     | 0 (0)     | 0.2839  |
| Admittance to ICU                  | 14 (6.4)                                                     | 1 (4.2)   | 0.6636  |
| Fatal outcome                       | 24 (11)                                                      | 1 (4.2)   | 0.2959  |

Discussion

Coinfections with SARS CoV-2 and bacterial, fungal, or viral pathogens may aggravate clinical conditions and pose challenges...
TABLE 4 Laboratory data in coinfected patients with severe acute respiratory syndrome coronavirus-2 and respiratory viruses aged <16 years and >65 years.

|                | <16 years age | >65 years age | p-Value  |
|----------------|---------------|---------------|----------|
| SARS-CoV-2     |               |               |          |
| co-infection   |               |               |          |
| with other respiratory viruses (n = 15) |               |               |          |
| Length of stay (hospital, days, mean) | 9              | 5.44          | 0.05     |
| PO₂ (mmHg, mean) | 96             | 85.2          | 0.018    |
| Lym (% mean)   | 19.7          | 10.9          | <0.01    |
| CRP (mg/L, mean) | 161.8         | 6.9           | <0.01    |

To investigate the intensity of viral replication during coinfection, we compared the viral load of SARS-CoV-2 with that of other respiratory viruses involved in coinfections. The mean viral load of SARS-CoV-2 was higher than that of the six with influenza viruses among children (3.2%) than among adult patients (0.3%; p < 0.01) (29).

In this study, HMPV, RSV, AdV, BoV, PIV, influenza A (H3N2), and RV were found to be involved in coinfections with SARS CoV-2. The most commonly identified virus was HMPV, followed by RSV, AdV, and BoV. We identified AdVs as co-detecting pathogens in four cases of coinfection, including one case with a fatal outcome. No cases of coinfections with seasonal coronaviruses were found. Other studies have reported that HMPV and AdV are the most frequent viral agents in SARS-CoV-2-positive patients after RV infection (10, 28, 30, 31). A study in the UK showed that SARS-CoV-2 coinfections with AdVs were significantly associated with increased odds of death (32). In the above-mentioned study in California, rhinovirus/enterovirus (6.9%), respiratory syncytial virus (5.2%), and non–SARS-CoV-2 Coronavirus (4.3%) have been most frequently identified (23). Other authors have also reported the highest incidence of mixed infections with RV/EV in SARS CoV-2 infected patients (10, 22, 26, 33). In the present study, only one coinfection including RV, was detected. The incidence of SARS CoV-2 coinfections with influenza viruses was also very low. During the COVID-19 pandemic in Bulgaria, the circulation of influenza viruses was unusually weak compared to the prepandemic seasons, and only two (0.8%) cases of coinfections with SARS CoV-2 were identified in 2022. Similar observations have also been reported in other countries. A systematic review and meta-analysis of 11 prevalence studies conducted during the first wave of the COVID-19 pandemic reported 0.8% prevalence of influenza viruses in patients with confirmed COVID-19 (34). In a large pan-India study, including 13,467 samples tested from July 4, 2021 to January 31, 2022, only five (0.04%) cases of SARS-CoV-2/influenza virus coinfections were detected (35). The general opinion is that public health efforts to control the spread of SARS CoV-2 led to a reduction in influenza virus transmission (31). Because the pathogenesis of both viral infections and receptor use differ, there is no receptor competition or viral interference, suggesting increased airway inflammation and aggravation of the clinical picture (36, 37). An animal model of SARS CoV-2/influenza coinfection demonstrated increased disease severity among hamsters coinfected with SARS-CoV-2 and influenza A compared to those with SARS-CoV-2 monoinfection (37). In our study, one case of influenza virus/SARS CoV-2 coinfection was a hospitalized patient and the other was an outpatient. The high viral load of influenza viruses in nasopharyngeal swabs confirms active infection and high infectivity. Fast and accurate diagnosis of influenza infection is important because of the increased risk of disease exacerbation and the need for early treatment with antiviral drugs.
co-detected respiratory viruses ($p < 0.001$). However, the mean viral load of the influenza virus was higher than that of SARS-CoV-2 and the six respiratory viruses involved in coinfections. These results indicate a more intensive replication of SARS-CoV-2 and influenza viruses compared to that of other respiratory viruses involved in coinfections. The level of the viral load involved in mixed infections depends largely on the time of exposure to one virus relative to the other. The importance of this factor was minimized by estimating the average viral load of the individual viruses involved in coinfection. Our findings can be explained by positive or negative interactions between SARS-CoV-2 and other respiratory viruses via interferon-mediated or other immunological mechanisms. To our knowledge, such studies have not been conducted in other countries; therefore, we were unable to compare our results with those of other studies.

To evaluate the impact of coinfection on disease severity, we compared the frequency of clinical symptoms, laboratory parameters, treatment approaches, and disease outcomes in patients with SARS-CoV-2 mono- and coinfection. The mean Ct value of SARS-CoV-2 was lower than that of other respiratory pathogens in cases of coinfections. Our findings contradict the opinion of some researchers who speculate that seasonal respiratory viruses (e.g., RV) have a shorter incubation period than SARS-CoV-2 and induce the production of interferon, which inhibits SARS-CoV-2 replication (38). Jeong et al. (24) reported that the median cycle threshold value of SARS-CoV-2 testing was slightly elevated in patients with coinfection. In another study, the differences in the mean Ct values between specimens with and without coinfection were not statistically significant (39). However, Burstein et al. (40) reported significant Ct differences ($p < 0.01$) between mono- and coinfected samples.

In the present study, fever, fatigue, and diarrhea were more frequently observed in patients with coinfections compared to those with monoinfections ($p < 0.05$). In coinfected febrile patients, the mean body temperature was higher than that in monoinfected patients ($38.7° \pm 0.7°C$ vs. $37.9° \pm 0.6°C$; $p<0.001$). Patients with coinfections had longer hospital stays than those with a single SARS-CoV-2 infection. The differences in CRP levels in the blood of mono- and coinfected patients >65 years of age were not statistically significant. No significant differences were observed in the treatment, need for high-flow oxygen therapy, or clinical outcomes. A similar comparison was made in a study in France, in which patients coinfected with SARS-CoV-2 and rhinovirus were significantly more likely to report a cough than those with SARS-CoV-2 monoinfection (62% vs. 31%; $p = 0.0008$) (10). However, a systematic review and meta-analysis reported no significant association between coinfection with SARS-CoV-2 and influenza and any of the clinical symptoms, such as fever, cough, and dyspnea. With respect to laboratory parameters such as white blood cells, CRP, IL-6, and IL2R, no significant differences were observed between the coinfection and monoinfection groups. Only lymphocyte counts were significantly higher in the coinfection group (41). These contradictory results require further study to better understand the impact of coinfections with different respiratory viruses on clinical presentation and disease outcome.

This study has some limitations. First, the analysis includes data from only two hospitals, which may not represent the Bulgarian COVID-19 patient group as a whole. Second, it is also not possible to establish a sufficient relationship in terms of mortality in co-infected patients compared to such cases in monoinfected patients, as only one case of a co-infected patient with a fatal outcome was considered in this study. Third, we consider the role of coinfections with influenza viruses other than A(H3N2) to be omitted due to the lack of circulation of A(H1N1)pdm09 and influenza type B viruses during the study period of November 2020 to March 2022 in Bulgaria. We accept as an omission in our study the restrictions on the sample size, due to which deviations in the selection and the possibility of evaluation are possible.

In conclusion, we evaluated the rate and clinical impact of coinfection with SARS-CoV-2 and other respiratory viruses in Bulgaria from November 2020 to March 2022. Our findings highlight the need for the maintenance of respiratory virus surveillance to understand the changing epidemiology of respiratory viruses during the period of relaxing public health and travel restrictions. The analysis of our clinical and laboratory data provided convincing evidence of the negative impact of coinfections on disease severity and outcome. In patients aged >65 years, coinfection with SARS-CoV-2 and other respiratory viral pathogens, along with concomitant diseases, can worsen the clinical picture and lead to a fatal outcome. These studies should continue, as they are important for effective patient management and containment of the epidemic.

**Data availability statement**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

**Author contributions**

IT conceptualized, designed the study. SA, RY, and TT were responsible for patient enrollment, assessment, and selection. IT, IM, SK, and NK performed the experiments. IT, IM, NK, SA, SV, RY, and TT analyzed the work results. IT and NK wrote the manuscript. IC reviewed the final manuscript. All authors read and approved the final manuscript.
Funding

This article is supported by: contracts K1-06-H 43/5/4.11.2020/ Molecular-genetic and clinical characteristics of human coronavirus. Study of the role of SARS-CoV-2 in co-infections with other respiratory viruses, NO KTI-0 6-DK1/7/29.03.2021/ Viral load, cytokines and serum antibody levels depending on the clinical severity of COVID-19 infection and by the European Regional Development Fund through Operational Program Science and Education for Smart Growth 2014–2020, Grant BG05M2OP001-1.002-0001-C04 Fundamental Translational and Clinical Investigations on Infections and Immunity.

Acknowledgments

Special thanks to the hospital team of Infectious Diseases Hospital Prof. Ivan Kirov in Sofia and that of the University Hospital Prof. Dr. Stoyan Kirkovich, Stara Zagora, who took the clinical samples, as well as for the analysis of clinical data.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin H, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res. (2020) 7:11. doi: 10.1186/s40779-020-00240-0
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. doi: 10.1056/NEJMo2001017
3. De Francesco MA, Pollizzi C, Gargiulo F, Giacomelli M, Caruso A. Circulation of respiratory viruses in hospitalized adults before and during the COVID-19 pandemic in Brescia, Italy: a retrospective study. Int J Environ Res Public Health. (2021) 18:9525. doi: 10.3390/ijerph181189525
4. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical characteristics of co-infections of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Viral. (2020) 92:2870–3. doi: 10.1002/jmv.26163
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
6. Kim E-H, Nguyen T-Q, Rollon MACR, Kim S-M, Kim Y-I, et al. Coinfection with SARS-CoV-2 and influenza virus increases disease severity and impairs neutralizing antibody and CD4 + T cell responses. J Virol. (2022) 96.e0187321. doi: 10.1128/jvi.01873-21
7. Stower JM, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, et al. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. Int J Epidemiol. (2021) 50:1124–33. doi: 10.1093/ijep/eyab081
8. Zheng J, Chen F, Wu K, Wang J, Li F, Lu SHJ, et al. Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients. PLoS Negl Trop Dis. (2021) 15:e0009997. doi: 10.1371/journal.pntd.0009997
9. Kumar N, Sharma S, Banka S, Tripathi BN, Rouse BT. Virological and immunological outcomes of coinfections. Clin Microbiol Rev. (2018) 31:17. doi: 10.1128/CMR.00111-17
10. Glass EL, Hoang VT, Bosch C, Ninove L, Lundt C, Boutin A, et al. Incidence and outcome of coinfections with SARS-CoV-2 and rhinovirus. Viruses. (2021) 13:2528. doi: 10.3390/v13112528
11. Mehta P, Sahn S, Siddiqui S, Mishra N, Sharma P, Sharma S., et al. Respiratory co-infections: modulators of SARS-CoV-2 patients' clinical sub-phenotype. Front Microbiol. (2021) 12:668.653399. doi: 10.3389/fmicb.2021.653399
12. Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, et al. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients. Sci China Life Sci. (2020) 63:606–9. doi: 10.1007/s11427-020-1668-5
13. Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. (2020) 53:50–12. doi: 10.1016/j.jmii.2020.05.013
14. Lansbury L, Lim B, Baskaran V et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. (2020) 81:266–75. doi: 10.1016/j.jinf.2020.05.046
15. Shu B, Wu KH, Emery S, Villanueva J, Johnson R, Guthrie E, et al. Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A(H1N1) pandemic influenza virus. J Clin Microbiol. (2011) 49:2614–9. doi: 10.1128/JCM.02270-10
16. Kodani M, Yang G, Conkin LM, Travi TC, Whitney CG, Anderson JJ, et al. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol. (2011) 49:2175–82. doi: 10.1128/JCM.02270-10
17. Lu X, Chittagangsy M, Olsen SJ, Mackay IM, Sloots TP, Fry AM, et al. Real-time PCR assays for detection of bocavirus in human specimens. J Clin Microbiol. (2006) 44:3231–5. doi: 10.1128/JCM.00889-06
18. Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis. (2020) 221:1668–98. doi: 10.1093/infdis/jju566
19. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome. JAMA. (2012) 307:2526–33.
20. Korsun NS, Angelova SG, Trifonova IT, Voleva SE, Grigorova IG, Tzotcheva IS, et al. The prevalence and genetic characterization of human metapneumovirus in Bulgaria, 2016–2019. Intervirology. (2021) 64:194–202. doi: 10.1159/000516821
21. Burrell S, Hausfater P, Dres M, Pourcher V, Luyt CE, Teyssou E, et al. Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. Int J Infect Dis. (2020) 102:10–3. doi: 10.1016/j.ijid.2020.10.040
22. Caso C, Zamagni G, Cozzi G, Tonegutto D, Ronfani L, De Manzini COA, et al. Spread of respiratory pathogens during the COVID-19 pandemic among children in the Northeast of Italy. Front Microbiol. (2022) 13:804700. doi: 10.3389/fmicb.2022.804700
23. Kim D, Quinn J, Pinky B, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. (2020) 323:2085–6. doi: 10.1001/jama.2020.6266

24. Jeong S, Lee N, Park Y, Kim J, Jeon K, Park M-J, et al. Prevalence and clinical impact of coinfection in patients with coronavirus disease 2019 in Korea. Viruses. (2022) 14:446. doi: 10.3390/v14020446

25. Nowak MD, Sordillo EM, Gitman MR, PanizMondolfi AE. Coinfection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? J Med Virol. (2020) 92:1699–700. doi: 10.1002/jmv.25953

26. Cooksey GLS, Morales C, Linde L, Schildhauer S, Guevara H, Chan E, et al. Severe acute respiratory syndrome coronavirus 2 and respiratory virus sentinel surveillance, California, USA, May 10, 2020-June 12, 2021. Emerg Infect Dis. (2022) 28:9–19. doi: 10.3201/eid2801.211682

27. Alhumaid S, Al Mutair A, Al Alawi Z, Alshawi AM, Alomran SA, Almuhanna MS, et al. Coinfections with bacteria, fungi, and respiratory viruses in patients with SARS-CoV-2: a systematic review and meta-analysis. Pathogens. (2021) 10:809. doi: 10.3390/pathogens10070809

28. Scott SJ, Potenilhaer R, Weiner J, Hillelsheim J, Khubber M, Bhattacharryya S. Respiratory pathogen coinfections in SARS-CoV-2-positive patients in southeastern wisconsin: a retrospective analysis. Microbiol Spectr. (2021) 9:e0083121. doi: 10.1128/Spectrum.00831-21

29. Dao TL, Hoang VT, Colson P, Million M, Gautret P. Co-infection of SARS-CoV-2 and influenza viruses: a systematic review and meta-analysis. J Clin Virol Plus. (2021) 1:100036. doi: 10.1016/j.jcvp.2021.100036

30. Kozinska A, Wegrzynska K, Komiazyk M, Walory J, Wasko I, Baraniak A. Viral Etiological agent(s) of respiratory tract infections in symptomatic individuals during the second wave of COVID-19 pandemic: an intra-household surveillance study. Viruses. (2021) 13:1598. doi: 10.3390/v13081598

31. Eisen AKA, Gularte JS, Demoliner M, Pereira VMAG, Heldt FH, Filippi M, et al. Low circulation of influenza A and coinfection with SARS-CoV-2 among other respiratory viruses during the COVID-19 pandemic in a region of southern Brazil. J Med Virol. (2021) 93:4392–8. doi: 10.1002/jmv.26975

32. Swets MC, Russell CD, Harrison EM, Docherty AR, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza virus, respiratory syncytial virus, or adenoviruses. Lancet. (2022) 399:1463–4. doi: 10.1016/S0140-6736(22)00383-X

33. Brotons P, Jordan I, Bassat Q, Henares D, de Sevilla MF, Ajanovic S, et al. The positive rhinovirus/enterovirus detection and SARS-CoV-2 persistence beyond the acute infection phase: an intra-household surveillance study. Viruses. (2021) 13:1598. doi: 10.3390/v13081598

34. Dadashi M, Kheighejnedj S, Elkhichi PA, Goudarzi M, Goudarzi H, Taghari A, et al. COVID-19 and influenza co-infection: a systematic review and meta-analysis. Front Med (Lausanne). (2021) 8:681469. doi: 10.3389/fmed.2021.61469

35. Aggarwal N, Potdar V, Vijuy N, Mukhopadhyay L, Manjusree BBS, Choudhary ML, et al. SARS-CoV-2 and influenza virus co-infection cases identified through ILI/SARI sentinel surveillance: a pan-India report. Viruses. (2022) 14:627. doi: 10.3390/v14030627

36. Kinoshita T, Watanabe K, Sakurai Y, Nishi K, Yoshikawa R, Yasuda J. Co-infection of SARS-CoV-2 and influenza virus causes more severe and prolonged pneumonia in hamsters. Sci Rep. (2021) 11:21259. doi: 10.1038/s41598-021-00809-2

37. Zhang AJ, Lee AC, Chan JF, Liu F, Li C, Chen Y, et al. Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden syrian hamsters. Clin Infect Dis. (2021) 72:978–e92. doi: 10.1093/cid/ciaa1747

38. Dee K, Goldfarb DM, Haney J, Amat JAR, Heider V, Stewart M, et al. Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology. J Infect Dis. (2021) 224:31–8. doi: 10.1093/infdis/jiaa147

39. Kim Z, Lee JH. Coinfection with severe acute respiratory syndrome coronavirus-2 and other respiratory viruses at a tertiary hospital in Korea. J Clin Lab Anal. (2021) 35:e23868. doi: 10.1002/jcla.23868

40. Burstein R, Althouse BM, Adler A, Akullian A, Brandstetter E, Cho S, et al. Interactions among 17 respiratory pathogens: a cross-sectional study using clinical and community surveillance data. medRxiv. (2022) 2022.02.04.22270474. doi: 10.1101/2022.02.04.22270474

41. Guan Z, Chen C, Li Y, Yan Y, Zhang X, Jiang D, et al. Impact of coinfection with SARS-CoV-2 and influenza on disease severity: a systematic review and meta-analysis. Front Public Health. (2021) 9:773130. doi: 10.3389/fpubh.2021.773130